Article Figures & Data
Figures
- Figure 1.
A, ROC curve for pentraxin-3 comparing all cases (N = 203) and all controls (N = 223). AUC = 0.66, 95% CI, 0.61 to 0.71. B, ROC curve for pentraxin-3 comparing all cases (N = 203) and high-risk controls (N = 180). AUC = 0.69, 95% CI, 0.64 to 0.75. C, ROC curve for pentraxin-3 comparing all cases (N = 203) and other cancer controls (N = 43). AUC = 0.54, 95% CI, 0.44 to 0.63.
Tables
- Table 1.
Sensitivity and specificity of pentraxin-3 in lung cancer patients
Specificity Sensitivity Versus high-risk controls a Versus all controls a Estimate 95% CI Estimate 95% CI 0.99 0.054 (0.000–0.158) 0.054 (0.000–0.133) 0.95 0.192 (0.094–0.296) 0.177 (0.118–0.281) 0.90 0.374 (0.212–0.478) 0.251 (0.163–0.399) 0.80 0.478 (0.394–0.557) 0.448 (0.365–0.542) 0.70 0.611 (0.493–0.734) 0.512 (0.419–0.611) 0.60 0.719 (0.621–0.783) 0.655 (0.542–0.734) 0.50 0.744 (0.670–0.798) 0.739 (0.680–0.808) -
↵aPlease see text for descriptions.
-
Supplementary Data
Supplementary Figures S1-S3.
Files in this Data Supplement:
- Supplementary Figures S1-S3 - Supplementary Figures S1-S3.
April 2011
Volume 17, Issue 8
Volume 17, Issue 8
Pentraxin-3 Is a Novel Biomarker of Lung Carcinoma
Jump to section
Advertisement